bioMerieux (OTCMKTS:BMXMF - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $152.00 and last traded at $152.00, with a volume of 100 shares changing hands. The stock had previously closed at $145.64.
Analyst Ratings Changes
Separately, Royal Bank Of Canada downgraded bioMerieux from a "moderate buy" rating to a "hold" rating in a research report on Wednesday, May 7th.
Get Our Latest Stock Report on BMXMF
bioMerieux Stock Performance
The firm has a fifty day moving average price of $142.63 and a 200 day moving average price of $131.76. The company has a current ratio of 2.20, a quick ratio of 1.29 and a debt-to-equity ratio of 0.08.
bioMerieux Company Profile
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider bioMerieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.
While bioMerieux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access